Bopindolol: pharmacological basis and clinical implications.

Abstract

Bopindolol, a non-selective antagonist of beta 1- and beta 2-adrenoceptors (ARs), has been found by pharmacological, molecular biological techniques and molecular modeling to have several unique properties. Bopindolol produces sustained blockade of beta 1- and beta 2-ARs, has intrinsic sympathomimetic as well as membrane stabilizing actions, inhibits renin secretion, and interacts with 5-HT receptors. Also, our recent molecular modeling studies identified possible interaction sites between bopindolol and beta-AR subtypes. The reviewed studies support our findings that bopindolol is non-selective for beta 1- and beta 2-ARs, has low affinity for beta 3-AR subtype and has pharmacological properties that are likely to be beneficial in the treatment of cardiovascular diseases.

• Authors: T Nagatomo, Y Hosohata, T Ohnuki, T Nakamura, K Hattori, J Suzuki, M Ishiguro
• Journal: Cardiovascular drug reviews (Cardiovasc Drug Rev) Vol. 19 Issue 1 Pg. 9-24 ( 2001) ISSN: 0897-5957 [Print] United States
• PMID: 11314603 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Adrenergic beta-Antagonists
• Receptors, Adrenergic, beta
• Receptors, Serotonin
• Pindolol
• Renin
• bopindolol

Topics

• Adrenergic beta-Antagonists (chemistry, pharmacokinetics, therapeutic use)
• Animals
• Cardiovascular Diseases (drug therapy)
• Disease Models, Animal
• Hemodynamics (drug effects)
• Models, Molecular
• Myocardial Contraction (drug effects)
• Pindolol (analogs & derivatives, chemistry, pharmacokinetics, therapeutic use)
• Receptors, Adrenergic, beta (chemistry, drug effects, metabolism)
• Receptors, Serotonin (drug effects, metabolism)
• Renin (antagonists & inhibitors, metabolism)